Olema Pharma Files 8-K on Material Definitive Agreement

TL;DR

**Olema Pharma just inked a major deal, watch for details on what it means for their future.**

AI Summary

Olema Pharmaceuticals, Inc. filed an 8-K on January 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." This filing indicates a significant new contract or partnership that could impact the company's future operations and financial health. For investors, this matters because material agreements often signal new revenue streams, strategic collaborations, or changes in business direction, which can directly influence the stock's valuation and future growth prospects.

Why It Matters

This filing signals a potentially significant business development for Olema Pharmaceuticals, Inc., which could lead to new opportunities or obligations that affect its financial performance and stock price.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its nature and potential impact, which could be positive or negative.

Analyst Insight

A smart investor would await further details on the "Material Definitive Agreement" to understand its financial implications before making any investment decisions regarding Olema Pharmaceuticals, Inc.

Key Players & Entities

• Olema Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• January 05, 2024 (date) — date of the earliest event reported in the 8-K
• Delaware (company) — state of incorporation for Olema Pharmaceuticals, Inc.
• 001-39712 (company) — Commission File Number for Olema Pharmaceuticals, Inc.
• OLMA (company) — trading symbol for Olema Pharmaceuticals, Inc. on Nasdaq

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share OLMA The Nasdaq Global Se
• $150 million — ng an aggregate offering price of up to $150 million. The issuance and sale, if any, of Shar
• $100.0 million — or an aggregate offering price of up to $100.0 million by any method deemed to be an “a

Filing Documents

• olma-20240105.htm (8-K) — 49KB
• olma-ex1_1.htm (EX-1.1) — 355KB
• olma-ex5_1.htm (EX-5.1) — 24KB
• 0000950170-24-002543.txt ( ) — 606KB
• olma-20240105.xsd (EX-101.SCH) — 2KB
• olma-20240105_lab.xml (EX-101.LAB) — 13KB
• olma-20240105_pre.xml (EX-101.PRE) — 10KB
• olma-20240105_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. “At the Market” Equity Offering Program On January 5, 2024, Olema Pharmaceuticals, Inc., or the Company, entered into a sales agreement, or the ATM Agreement, with Cowen and Company, LLC, or TD Cowen, as sales agent, pursuant to which the Company may offer and sell, from time to time through TD Cowen, at its option, shares of its common stock, par value $0.0001 per share, or the Shares, having an aggregate offering price of up to $150 million. The issuance and sale, if any, of Shares under the ATM Agreement will be pursuant to the Company’s registration statement on Form S-3 (File No. 333-263117), which became effective on May 2, 2022, and the related prospectus supplement dated January 5, 2024, in each case filed with the U.S. Securities and Exchange Commission. Pursuant to the ATM Agreement, the Company may sell Shares in amounts and at times to be determined by it from time to time through TD Cowen and subject to the terms and conditions of the ATM Agreement, but the Company has no obligation to sell any of the Shares under the ATM Agreement. The sales, if any, of the Shares will be made by any method permitted that is deemed to be an “at-the-market” equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through the Nasdaq Global Select Market. The offer and sale of the Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the issuance and sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement. The Company has agreed to pay TD Cowen a commission of up to 3.0% of the aggregate gross proceeds from any Shares sold by TD Cowen and to provide TD Cowen with customary indemnification and contribution rights, including for liabilities under the Securities Act and the Securities Exchange Act, as amended.

Forward-Looking Statements

Forward-Looking Statements

01 Other Events

Item 8.01 Other Events. Termination of Prior “At the Market” Equity Offering Program In connection with its entry into the ATM Agreement, on January 5, 2024, the Company terminated its prior sales agreement, dated as of March 9, 2023, or the Prior Agreement, by and between the Company and Oppenheimer & Co., Inc., or Oppenheimer, in accordance with its terms. The Prior Agreement provided for Oppenheimer to sell shares of the Company’s common stock for an aggregate offering price of up to $100.0 million by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. No sales of common stock were made under the Prior Agreement. The Company cannot make any future sales of its common stock pursuant to the Prior Agreement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 Sales Agreement by and between Registrant and Cowen and Company, LLC, dated January 5, 2024 . 5.1 Opinion of Cooley LLP . 23.1 Consent of Cooley LLP (included in Exhibit 5.1) . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OLEMA PHARMACEUTICALS, INC. Date: January 5, 2024 /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR